Abate Kristin 4

What Happened Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics (KPTI), sold 265 shares on 2026-01-21 at $5.96 per share, generating proceeds of $1,579. The filing indicates this was a broker-assisted sale to satisfy withholding tax liability from the vesting of restricted stock units and was not a discretionary trade.

Key Details

• Transaction type: Sale (Code S)
• Date: 2026-01-21; Price: $5.96 per share; Total proceeds: $1,579
• Footnote: Sale effected under a durable automatic sale instruction plan adopted May 27, 2021; sale to cover tax withholding on RSU vesting (not discretionary)
• Filing: Reported on Form 4 filed 2026-01-22 (timely)
• Shares owned after transaction: Not specified in the information provided

Context Sales to cover tax withholding on vested restricted stock units are routine and reflect tax obligations rather than a proactive decision to reduce holdings. This small, single transaction ($1.6k) should be viewed differently than a voluntary large insider sale; purchases or voluntary sales usually carry more interpretive weight for investor sentiment.